About Pacific GeneTech
Pacific GeneTech is a company based in Hong Kong (China) founded in 2009. Pacific GeneTech has raised $10 million across 1 funding round from investors including Arkansas.gov, Simmons Foods and WHIST. Pacific GeneTech offers products and services including Aegis Vaccine Platform, Hercules Adjuvant System, and Salmonella Vaccine. Pacific GeneTech operates in a competitive market with competitors including Biological E, Insmed, Affinivax, Merck Animal Health and Altimmune, among others.
- Headquarter Hong Kong, China
- SectorsHealthcareAgriculture
- Email••••••••
- Phone•••• ••••
- Website pacificgenetech.com
- Social LinkedIn
- Legal Name Pacific Genetech Limited
- Total Equity Funding$10M (USD)
in 1 rounds
- Latest Funding Round$10M (USD), Series A
Aug 2022
- InvestorsArkansas.gov
& 3 more
Products & Services of Pacific GeneTech
Pacific GeneTech offers a comprehensive portfolio of products and services, including Aegis Vaccine Platform, Hercules Adjuvant System, and Salmonella Vaccine.
Enables broad-spectrum protection for vaccines against pathogens
Supports administration of inactivated vaccines for enhanced efficacy
Targets Salmonella in poultry and livestock for disease prevention
Funding Insights of Pacific GeneTech
Pacific GeneTech has successfully raised a total of $10M through 1 strategic funding round. The most recent funding activity was a Series A round of $10 million completed in August 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $10M
- Total Rounds 1
- Last Round Series A — $10M
- First Round $10M
(Aug 2022)
- Investors Count 4
All 1 funding rounds of Pacific GeneTech with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2022 | $10M | Series A | – | – |
4 investors in total: 4 institutional.
Investors in Pacific GeneTech
Pacific GeneTech has secured backing from 4 investors, including institutional investors. Prominent investors backing the company include Arkansas.gov, Simmons Foods and WHIST.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Simmons Foods is engaged in poultry and pet food production. | 1949 | simmonsfoods.com | Siloam Springs, United States | |
Access to government programs and development services is provided. | 1995 | arkansas.gov | United States | |
Women's health and empowerment services are provided in South Tyneside. | 1986 | whist.org.uk | South Shields, United Kingdom | |
Distributes high-quality products for livestock, agriculture, and pet care in Indonesia. | 1976 | medion.co.id | Bandung, Indonesia |
Investor details for Pacific GeneTech
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Pacific GeneTech
1 people are tracked at Pacific GeneTech (1 in leadership).
| Name | Role | Group |
|---|---|---|
Tim Collard | CEO | Leadership |
Complete people profiles for Pacific GeneTech
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Pacific GeneTech
2 dated milestones of Pacific GeneTech across 13 years, from founding to its latest funding, stage changes and deals.
- Founded Pacific GeneTech is founded.
- Funding First funding round of $10.0M.
Competitors of Pacific GeneTech
Pacific GeneTech operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biological E, Insmed, Affinivax, Merck Animal Health and Altimmune, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| biologicale.com | 1953 | Hyderabad, India | – | 6,099 | Vaccines and therapeutics for multiple diseases are developed and marketed. | |
| insmed.com | 1999 | Bridgewater, United States | – | 912 | Developer of small molecule inhibitors for rare lung diseases | |
| affinivax.com | 2013 | Cambridge, United States | $359.49M | 132 | Technology-based conjugate vaccines against infectious diseases are developed. | |
| merck-animal-health.com | 1921 | Madison, United States | – | 2,952 | Vaccine technology is developed and supplied for livestock animals. | |
| altimmune.com | 1997 | Gaithersburg, United States | $58M | 17 | Vaccines for infectious diseases and solid tumors are developed. | |
| vaxart.com | 2004 | San Francisco, United States | $57.97M | 110 | Developer of therapeutic solutions for treating multiple infectious diseases | |
| eligo.bio | 2014 | Paris, France | $52.26M | – | In vivo gene editing technology is developed for microbiome modulation. | |
| lodotherapeutics.com | 2015 | New York, United States | $19.87M | 24 | Developer novel therapeutics to treat resistant infectious diseases and cancers using AI | |
| symbiomix.com | 2012 | Newark, United States | $66.55M | – | Late-stage biopharma antibiotics for gynecological infections are developed. |
Detailed competitors of Pacific GeneTech
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Pacific Genetech
Complete news archive for Pacific GeneTech
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Pacific GeneTech
10 companies that operate in the same segment as Pacific GeneTech (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Pacific GeneTech
Pacific GeneTech was founded in 2009 and raised its 1st funding round 13 years after it was founded.
Pacific GeneTech is headquartered in Hong Kong, China.
Tim Collard is the current CEO of Pacific GeneTech.
Pacific GeneTech is a funded company, having raised a total of $10M across 1 funding round to date. The company's 1st funding round was a Series A of $10M, raised on Aug 2022.
Pacific GeneTech was founded in 2009 in Hong Kong, China, within the biotechnology sector. Vaccines targeting viral, bacterial, and parasitic diseases in animals and humans are developed using microbial vectors via the Aegis Vaccine Platform for gene insertion. Operations focus on gene delivery systems, with a pipeline that includes PGT Hercules Adjuvant, a modified chitosan applied to multiple disease indications.
Pacific GeneTech's top competitors include Biological E, Insmed and Vaxart.
Pacific GeneTech offers Aegis Vaccine Platform, Hercules Adjuvant System, and Salmonella Vaccine.
Pacific GeneTech has 4 investors. Key investors include Arkansas.gov, Simmons Foods, WHIST, and PT Medion Ardhika Bhakti.
Pacific GeneTech operates through Pacific Genetech Limited.